Why a complete response is the treatment aim in chronic spontaneous urticaria

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Bernstein, Jonathan A.
• dc.contributor.author Giménez Arnau, Anna Maria
• dc.contributor.author Maurer, Marcus
• dc.contributor.author Staubach, Petra
• dc.contributor.author Barbier, Nathalie
• dc.contributor.author Hua, Eva
• dc.contributor.author Severin, Thomas
• dc.contributor.author Laires, Pedro A.
• dc.contributor.author Balp, Maria Magdalena
• dc.date.accessioned 2023-09-20T06:53:32Z
• dc.date.available 2023-09-20T06:53:32Z
• dc.date.issued 2023
• dc.description.abstract This study investigated the association between urticaria activity and health-related quality of life (HRQoL). Patient evaluations from the ligelizumab Phase 2b clinical trial (N = 382) were pooled (NCT02477332). Daily patient diaries assessed urticaria activity, sleep and activity interference, the dermatology life quality index (DLQI), and work productivity and activity impairment-chronic urticaria (WPAI-CU). The number of DLQI scores, weekly sleep interference scores (SIS7), weekly activity interference scores (AIS7), and overall work impairment (OWI) evaluations with a complete response per weekly urticaria activity score (UAS7) using bands (0, 1-6, 7-15, 16-27, and 28-42) were reported. Over 50% of the patients had a mean DLQI of > 10 at baseline, indicating a significant effect of chronic spontaneous urticaria (CSU) on their HRQoL. Complete response (UAS7 = 0) evaluations corresponded with no impacts on other patient-reported outcomes. In total, 91.1% of UAS7 = 0 evaluations corresponded to DLQI scores of 0-1, 99.7% to SIS7 scores of 0, 99.7% to AIS7 scores of 0, and 85.3% to OWI scores of 0. This was significantly different compared with the UAS7 = 1-6 evaluations (61.9%, 68.5%, 67.7%, and 65.4%, respectively; p < 0.0001). Complete responses to treatment were associated with no impairments on the dermatology-QoL, no interferences with sleep and activity, and significantly improved capacities to work compared to patients who continued to have signs and symptoms, even for those with minimal disease activity.
• dc.format.mimetype application/pdf
• dc.identifier.citation Bernstein JA, Giménez-Arnau A, Maurer M, Staubach P, Barbier N, Hua E, Severin T, Laires PA, Balp MM. Why a complete response is the treatment aim in chronic spontaneous urticaria. J Clin Med. 2023;12(10):3561. DOI: 10.3390/jcm12103561
• dc.identifier.doi http://dx.doi.org/10.3390/jcm12103561
• dc.identifier.issn 2077-0383
• dc.identifier.uri http://hdl.handle.net/10230/57926
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof J Clin Med. 2023;12(10):3561
• dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Chronic spontaneous urticaria
• dc.subject.keyword Complete response
• dc.subject.keyword Patient-reported outcomes
• dc.subject.keyword Quality of life
• dc.subject.keyword Sleep
• dc.title Why a complete response is the treatment aim in chronic spontaneous urticaria
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion